| |

Empower Psychedelics: Harnessing the Powers of Running on Acid

Empower Psychedelics
Empower Psychedelics

As the modern psychedelic renaissance continues to rise, there are more companies and organizations than ever dedicated to evangelizing on behalf of these compounds. While most focus on microdosing, one group is setting themselves apart by touting the benefits of hero doses, specifically of LSD.

Empower Psychedelics is a Canadian non-profit developing strategic environments for the legal use of entheogenic medicine. Focusing on using LSD as a key component of physical therapy and rehabilitation, Empower has seen incredible results when combining the drug with exercise. In addition to boosting benefits, the team found that physical activity actually aids in navigating a trip with ease.

The co-founders of Empower were inspired to start the organization after finding success in integrating exercise with their own psychedelic journeys. 

“The practice was groundbreaking personally as it enabled me to push well outside my comfort zone during training, particularly while recovering from body injuries. It was also an effective means of controlling higher doses of psychedelics,” they said.

In order to raise awareness and funding for their research, Empower launched the Running on Acid project. What began as a collection of original artwork inspired by various psychedelic trips, became the foundation for Empower to establish psychedelic therapy centers and clinical programs. They are now pursuing outside investment to expand their reach.

Initial research with first responders in group therapy settings has shown immense promise, helping those on the front lines of fires, accidents, and other emergencies heal both the body and mind.

“The response within the first responder community has been overwhelmingly positive, even above and beyond what we had hoped for,” the team said. “The sad reality is that rates of trauma, PTSD, depression, anxiety, and other psychological ailments are rising, somewhat unchecked, within these populations. Many traditional treatments are not the right fit or are ineffective for some, leaving many feeling hopeless and unsure of where to turn. We hope to help create a new, effective, and exciting avenue for treatment of these conditions and more.”

 

Similar Posts

  • MindMed Releases LSD for Anxiety Data ! (MNMD, MMED)

    Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
    www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

    Join our Newsletter (scroll to the bottom of the page and sign up):
    https://psychedelicspotlight.com/

    Follow us on Twitter:
    The Psychedelic Investor: @PSYCBiz
    Psychedelic Spotlight: @PsycSpotlight

    Follow us on Instagram:
    @psycbiz
    @psycspotlight

    ❗❗❗ The Psychedelic Investor will be changing its name to PSYC Business very soon.
    Stay tuned for more updates!

    In today’s episode, we discuss MindMed (Nasdaq: MNMD, NEO:MMED) and its Phase 2 LSD Trial Treating Anxiety Results.

    MindMed (Nasdaq: MNMD, NEO:MMED) finally gave the world a glimpse into its LSD-as-medicine project today.

    Speaking at the highly anticipated PSYCH Symposium in London, researchers Prof. Matthias Liechti and Dr. Friederike Holze presented topline data of a Phase 2, double-blind, placebo-controlled study, attempting to treat anxiety disorders with LSD in 46 patients. Patients received 200 µg (micrograms) of LSD, which is considered a large dose.

    The results were very positive, though perhaps not paradigm shifting — yet.

    The primary endpoint of the study was the reduction in anxiety levels 16 weeks after the administration of LSD. They measured this using a questionnaire called the State Trait Anxiety Inventory, better known by its acronym STAI. In short, a person can have a score between 0 and 63, with the higher the score, the worse the anxiety.

    The study found that 65% of patients saw their anxiety levels drop by at least 30% from where they were before treatment, 16 weeks after dosing. This compared to only 9% of patients in the placebo arm reaching that 30% level. The average reduction in the STAI was 16.2 points.

    Importantly, there was only one serious adverse event in the trial, which consisted of “acute transient anxiety and delusions” during the LSD experience. It does not appear that this patient had any troubles once the effects wore off. In sum, the administration of large doses of LSD appears to be very safe, even if one person did have a particularly bad experience during the dosing.

    Furthermore, when looking at secondary variables that measure depression, anxiety and other major psychiatric symptoms (Hamilton Depression Scale, Beck Depression Index, Symptom-Check-List-90-R) the results “showed similarly rapid and sustained responses consistent with a lasting treatment effect.”

    In sum, according to MindMed, the topline data demonstrates “the significant, rapid, durable, and beneficial effects of LSD and potential to safely mitigate symptoms of anxiety and depression.”

    Interested in reading the article? Click here: 👇

    MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success
    https://psychedelicspotlight.com/mindmed-lsd-anxiety-phase-2-trial-psych-symposium/

    #MindMed #Anxiety #MNMD

  • The Psychedelic Sector has Reached “Escape Velocity” | An interview with Cybin’s CEO (CYBN)

    In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin (NYSE: CYBN) for the Psychedelic Spotlight podcast.

    In the interview, the two discuss Cybin’s psychedelic medicines portfolio, and where the psychedelic industry is going in the next few years. Can psychedelics heal mental health?

    The main topic was attempting to answer the question: can psilocybin heal mental health conditions like depression?

    Doug Drysdale spoke on the positive results we have seen in psilocybin for depression clinical trials, such as the Compass Pathways’ psilocybin (comp 360) for treatment-resistant depression phase 2b trial. Despite the apparent benefits of psilocybin, though, Doug Drysdale and Cybin argued that there were 3 core problems with using psilocybin in a therapy setting: the long duration of effect; the onset action period; and the variability of effect.

    Cybin has developed a new version of psilocybin, called CYB-003. CYB-003 has a shorter duration, reaches peak effect quicker, and has less variability in effect between individuals. Plus, it keeps all of the therapeutic benefits of psilocybin and its subjective effects.

    It is important to note that Cybin’s Cyb-003, their next-generation psilocybin, has only been tested in animals up until this point. They intend to start human clinical trials next year.

    James and Doug of Cybin also discussed the other Cybin projects, such as CYB-004, and their development strategy. They also discussed government policy, and whether the psychedelics sector has reaches escape velocity.

    In all, this psychedelic medicines conversation was fascinating and showed Cybin’s dedication towards improving mental health conditions, which are abysmal in the United States right now.

    Enjoy the episode!

    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor
    James’ Twitter: @Psy_Invest
    Maria’s Twitter (Producer & Editor): @Psy_Holy
    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #Cybin #Psilocybin #Psychedelics